Abstract
Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gore, M., Fryatt, I., Wiltshaw, E. et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60, 767–769 (1989). https://doi.org/10.1038/bjc.1989.356
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.356
This article is cited by
-
Systems biology of cisplatin resistance: past, present and future
Cell Death & Disease (2014)
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Oncogene (2003)
-
Pharmacokinetics and antitumor activity of a new platinum compound,cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl- 1, 3-dioxolane]platinum(II), as determined by ex vivo pharmacodynamics
Cancer Chemotherapy and Pharmacology (1995)
-
Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethy1)-2-isopropyl-1,3-dioxolanelplatinum(II), a new platinum analogue, as an anticancer agent
Cancer Chemotherapy and Pharmacology (1995)
